Pharma R&D Today

3 issues global pharmas should consider as the coronavirus outbreak continues

Posted on February 26th, 2020 by Xuanyan Xu in COVID-19

It has been more than four weeks since the Wuhan lockdown on January 23. As the crisis unfolded, spring festival national holidays were extended (and extended again), and finally people are now gradually going back to work—though some cities, towns and villages are still taking strict measures to prevent the virus spreading further.

What’s ahead for the Life Sciences industry?

Posted on December 30th, 2019 by Neal Katz in Pharma R&D

As the year comes to a close, we’re thinking about trends in the landscape and where the industry is headed. What do some of the members of Elsevier’s Life Sciences team think?

Tom Pianko VP of Global Key Accounts, counts machine learning, artificial intelligence, data normalization and advance analytics tools among the trends that point to where the Life Sciences industry is going—and many of his colleagues agree.

‘Tis the season to have your own pharma-themed film festival

Posted on December 23rd, 2019 by Xuanyan Xu in Pharma R&D

The warmest family celebration of the year is almost here! All my friends and colleagues around me have started thinking about the best ways to spend this year’s family gathering. Well, if you are like me—a geeky introvert who enjoys time alone—nothing goes better with family parties and eating huge amounts of food than relaxing on the couch and binge-watching movies and TV shows.

Global Dominance in AI? China’s Got a Plan For That

Posted on July 9th, 2019 by Xuanyan Xu in Pharma R&D

Artificial intelligence is more than just a ‘hot topic’ in the pharmaceutical industry—it is actually influencing the way that major industry players and even entire nations are thinking about the future. As more AI-focused companies are launching, and as investment in AI technology is increasing in the US and EU, China is speeding up its efforts to ensure that it can be competitive in this burgeoning area.